Atea Pharmaceuticals
AVIR
106 hedge funds and large institutions have $190M invested in Atea Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 10 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
20% more capital invested
Capital invested by funds: $158M → $190M (+$31.4M)
3% more funds holding
Funds holding: 103 → 106 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.33% less ownership
Funds ownership: 61.9% → 61.57% (-0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$679K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$514K |
| 3 |
Two Sigma Advisers
New York
|
+$501K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$476K |
| 5 |
Two Sigma Investments
New York
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.73M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$890K |
| 3 |
BlackRock
New York
|
-$819K |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
-$804K |
| 5 |
D.E. Shaw & Co
New York
|
-$443K |
AVIR Hedge Fund Activity: Q2 2025 in Review
106 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2025, worth a combined $190M — up 20% from $158M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AVIR positions and 10 closed out — a net gain of 3 holders — while 36 added to existing stakes and 27 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $679K. The largest seller was Federated Hermes, cutting an estimated $1.73M.
- 106 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2025, up from 103 in Q1 2025.
- Funds reported $190M of Atea Pharmaceuticals stock for Q2 2025, up 20% quarter-over-quarter.
- 13 funds opened new Atea Pharmaceuticals positions in Q2 2025 and 10 closed out, a net change of +3 holders.
- The largest Atea Pharmaceuticals buyer in Q2 2025 was Dimensional Fund Advisors, an estimated $679K added.
- The largest Atea Pharmaceuticals seller in Q2 2025 was Federated Hermes, an estimated $1.73M sold.
Based on aggregated 13F filings for Q2 2025.